Organization
The Ohio State University James Cancer Center
16 abstracts
Abstract
Detection of peritoneal metastases during cytoreductive surgery using pegsitacianine, a pH sensitive imaging agent: Final results from a phase 2 study.Org: Wake Forest University Department of General Internal Medicine, Wake Forest Baptist Health, University of Pennsylvania, OncoNano Medicine, Allegheny Health Network Cancer Institute,
Abstract
Dostarlimab for primary advanced or recurrent (A/R) endometrial cancer (EC): Outcomes by blinded independent central review (BICR) of the RUBY trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).Org: US Oncology Research, HonorHealth Research Institute, Creighton University School of Medicine, The Ohio State University James Cancer Center, Division of Gynecologic Oncology,
Abstract
Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), safety and efficacy in a broad distribution of FolRα expression in patients with recurrent epithelial ovarian cancer (OC): Update of STRO-002-GM1 phase 1 dose expansion cohort.Org: Vall d’Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, The Ohio State University James Cancer Center, Sidney Kimmel Cancer Center at Thomas Jefferson University, University of Chicago,
Abstract
A phase II/III study of peri-operative nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: Results of the neoadjuvant pathologic complete response (pCR) rate (ECOG-ACRIN EA2174).Org: University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA, Dana-Farber Cancer Institute, Boston, MA,
Abstract
Multi-site randomized trial of a collaborative palliative and oncology care model for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) receiving non-intensive therapy.Org: Massachusetts General Hospital, Boston, MA, Harvard Medical School, The Ohio State University Wexner Medical Center, Columbus, OH,
Abstract
Outcome of children and young adults with localized extremity rhabdomyosarcoma treated on Children's Oncology Group trials.Org: CancerCare Manitoba, University of Florida-Health Cancer Center, Orlando Health, Orlando, FL, The Ohio State University James Cancer Center, H. Lee Moffitt Cancer Center and Research Institute, Cincinnati Children's Hospital Medical Center,
Abstract
CINSARC score use in pediatric non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) in the Children’s Oncology Group (COG) studies ARST0332 and ARST1321.Org: Children's Hospital of Philadelphia, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, Children's Oncology Group Statistics and Data Center, University of Florida, Massachusetts General Hospital, Seattle Children's Hospital,
Abstract
SU2C-SARC032: A randomized trial of neoadjuvant RT and surgery with or without pembrolizumab for soft tissue sarcoma.Org: UPMC Hillman Cancer Center, Mayo Clinic Rochester, Melanoma Institute Australia, University of Sydney and Sydney Cancer Centre, Chris O'Brien Lifehouse,
Abstract
Alliance A222001: A randomized, double-blind, placebo controlled phase II study of oxybutynin versus placebo for the treatment of hot flashes in men receiving androgen deprivation therapy.Org: Mayo Clinic Department of Radiation Oncology, Rochester, MN, Mayo Clinic, Phoenix, AZ, Division of Hematology & Medical Oncology,
Abstract
Trends in mortality from secondary malignancy in the United States, 1999-2019.Org: The Ohio State University James Cancer Center, Dow University of Health Sciences, University of Toledo, UNC Nash General Hospital, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA,
Abstract
Persistent poverty impacts survival and National Comprehensive Cancer Network guideline-concordant care for patients with melanoma.Org: The Ohio State University College of Medicine, The Ohio State University Wexner Medical Center, The Ohio State University James Cancer Center,
Abstract
NFKBIA deletions reshape the epigenome antithetical to the IDH mutation and indication of prognosis in diffuse gliomas.Org: University of Alabama at Birmingham School of Medicine, Institut Mar d'Investigacions Mèdiques, NRG Oncology and The University of Florida Health Cancer Center, The Ohio State University James Cancer Center,
Abstract
First-in-human phase I trial of the oral first-in-class ubiquitin specific peptidase 1 (USP1) inhibitor KSQ-4279 (KSQi), given as single agent (SA) and in combination with olaparib (OLA) or carboplatin (CARBO) in patients (pts) with advanced solid tumors, enriched for deleterious homologous recombination repair (HRR) mutations.Org: KSQ Therapeutics, Cambridge, MA, Roche Pharma Research and Early Development, Roche Innovation Center, Dana-Farber Cancer Institute, Hackensack University Medical Center,
Abstract
Upregulation of GREB1 in colorectal cancer ovarian metastases may be a potential therapeutic target.Org: The Ohio State University - James Cancer Hospital, The Ohio State University Wexner Medical Center, UC Irvine, The Ohio State University James Cancer Center,
Abstract
De-correlating immune checkpoint inhibitor toxicity and response in melanoma via the microbiome.Org: Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, The Ohio State University - James Cancer Hospital, Ohio State University College of Medicine, The Ohio State University Medical Center,
Abstract
Salvage lenvatinib/everolimus (LE) combination therapy after immune checkpoint inhibitor (ICI) and VEGFR tyrosine kinase inhibitor (TKI) for metastatic renal cell carcinoma (mRCC).Org: The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, University of Washington and Fred Hutchinson Cancer Research Centre, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, The Ohio State University James Cancer Center, The James Cancer Hospital and Solove Research Institute,